Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 2
1962 1
1967 1
1969 1
1970 2
1971 5
1973 4
1974 1
1975 5
1976 6
1977 1
1978 1
1979 1
1981 2
1982 1
1983 2
1987 1
1989 2
1990 4
1991 1
1992 2
1993 1
1994 2
1995 4
1996 2
1997 4
1998 1
1999 2
2000 4
2001 3
2002 4
2003 8
2004 8
2005 6
2006 9
2007 14
2008 14
2009 10
2010 17
2011 15
2012 19
2013 21
2014 19
2015 15
2016 19
2017 16
2018 20
2019 20
2020 23
2021 23
2022 20
2023 25
2024 24
2025 24

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

415 results

Results by year

Filters applied: . Clear all
Page 1
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial.
Aronson SL, Lopez-Yurda M, Koole SN, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van Gent MDJM, Arts HJG, van Ham MAPC, van Dam PA, Vuylsteke P, Aalbers AGJ, Verwaal VJ, Van de Vijver KK, Aaronson NK, Sonke GS, van Driel WJ. Aronson SL, et al. Among authors: van ham mapc. Lancet Oncol. 2023 Oct;24(10):1109-1118. doi: 10.1016/S1470-2045(23)00396-0. Epub 2023 Sep 11. Lancet Oncol. 2023. PMID: 37708912 Clinical Trial.
The immunoproteasome disturbs neuronal metabolism and drives neurodegeneration in multiple sclerosis.
Woo MS, Brand J, Bal LC, Moritz M, Walkenhorst M, Vieira V, Ipenberg I, Rothammer N, Wang M, Dogan B, Loreth D, Mayer C, Nagel D, Wagner I, Pfeffer LK, Landgraf P, van Ham M, Mattern KM, Winschel I, Frantz N, Sonner JK, Grosshans HK, Miguela A, Bauer S, Meurs N, Müller A, Binkle-Ladisch L, Salinas G, Jänsch L, Dieterich DC, Riedner M, Krüger E, Heppner FL, Glatzel M, Puelles VG, Engler JB, Nyengaard JR, Misgeld T, Kerschensteiner M, Merkler D, Meyer-Schwesinger C, Friese MA. Woo MS, et al. Among authors: van ham m. Cell. 2025 Aug 21;188(17):4567-4585.e32. doi: 10.1016/j.cell.2025.05.029. Epub 2025 Jun 17. Cell. 2025. PMID: 40532699 Free article.
Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D, Zivanovic O, Mosgaard BJ, Fagotti A, Colombo PE, Sonke G, Driel WJV; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group. Koole S, et al. Int J Gynecol Cancer. 2020 Jun;30(6):888-892. doi: 10.1136/ijgc-2020-001231. Epub 2020 Mar 23. Int J Gynecol Cancer. 2020. PMID: 32205449 Free PMC article.
Gastroduodenal defense.
Ham M, Kaunitz JD. Ham M, et al. Curr Opin Gastroenterol. 2007 Nov;23(6):607-16. doi: 10.1097/MOG.0b013e3282f02607. Curr Opin Gastroenterol. 2007. PMID: 17906436 Review.
Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1).
Aronson SL, Walker C, Thijssen B, van de Vijver KK, Horlings HM, Sanders J, Alkemade M, Koole SN, Lopez-Yurda M, Lok CAR; OVHIPEC-1 Study Group; Rottenberg S, van Rheenen J, Sonke GS, van Driel WJ, Kester LA, Hahn K. Aronson SL, et al. Br J Cancer. 2024 Aug;131(3):565-576. doi: 10.1038/s41416-024-02731-6. Epub 2024 Jun 12. Br J Cancer. 2024. PMID: 38866963 Free PMC article. Clinical Trial.
415 results